{
    "clinical_study": {
        "@rank": "122608", 
        "arm_group": [
            {
                "arm_group_label": "Phase Ib", 
                "arm_group_type": "Experimental", 
                "description": "The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. Patients with either measurable or evaluable disease will be eligible. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study."
            }, 
            {
                "arm_group_label": "Phase II", 
                "arm_group_type": "Experimental", 
                "description": "The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Data from enrolled patients will also be used to better characterize the safety, tolerability and PK profile of the two agents. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part."
            }
        ], 
        "brief_summary": {
            "textblock": "In the phase Ib, the primary purpose is to establish the maximum tolerated dose\n      (MTD)(s)/recommended phase ll dose (RP2D) and schedule of  LEE011 and MEK162 orally\n      administered combination. Once the MTD(s)/RP2D have been determined for each tested\n      schedule, additional patients will be enrolled in the phase II portion of the study at the\n      RP2D on the chosen schedule in order to assess the anti-tumor activity of the combination in\n      addition to continued evaluation of safety."
        }, 
        "brief_title": "A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Locally Advanced or Metastatic NRAS Mutant Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of\n             0 - 1.\n\n          -  Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients\n             enrolled into the phase II expansion must have at least one measurable lesion as\n             defined by RECIST 1.1 criteria for solid tumors.\n\n          -  Patients must have adequate organ function, as defined by the following parameter\n\n               1. Absolute Neutrophil Count (ANC) \u2265 1.5 x 109/L.\n\n               2. Hemoglobin (Hgb) \u2265 9 g/dL.\n\n               3. Platelets \u2265 75 x 109/L without transfusions within 21 days before 1st treatment.\n\n               4. PT/INR and aPTT \u2264 1.5 ULN.\n\n               5. Serum creatinine \u22641.5 ULN.\n\n               6. Serum total bilirubin \u2264 1.5 x upper limit of normal (ULN).\n\n               7. AST and ALT \u2264 3 x ULN, except in patients with tumor involvement of the liver\n                  who must have AST and ALT \u2264 5 x ULN.\n\n        Exclusion Criteria:\n\n          -  Presence of any brain metastases detected by MRI or CT with i.v. contrast of the\n             brain at screening.\n\n          -  Uncontrolled arterial hypertension despite medical treatment\n\n          -  Impaired cardiac function or clinically significant cardiac diseases, including any\n             of the following:\n\n               1. Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated\n                  acquisition scan (MUGA) or echocardiogram (ECHO).\n\n               2. Congenital long QT syndrome or family history of unexpected sudden cardiac\n                  death.\n\n               3. QTcF corrected with Frederica's or Bazett's formula QTcB >450 ms for males and\n                  >470 ms for females on screening ECG.\n\n               4. Angina pectoris \u2264 3 months prior to starting study drug\n\n               5. Acute myocardial infarction \u2264 3 months prior to starting study drug\n\n               6. Clinically significant resting bradycardia\n\n               7. History or presence of ventricular tachyarrhythmia\n\n               8. Unstable atrial fibrillation (ventricular response >100 bpm)\n\n               9. Complete left bundle branch block\n\n              10. Right bundle branch block and left anterior hemi block (bifascicular block)\n\n              11. Obligate use of a cardiac pacemaker or implantable cardioverter defibrillator\n\n              12. Any other clinically significant heart disease\n\n          -  Patients who are currently receiving treatment with agents that are known to cause\n             QTc prolongation in humans.\n\n          -  Patients who have neuromuscular disorders that are associated with elevated CK (e.g.,\n             inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal\n             muscular atrophy) or elevated baseline CK levels (\u2265 Grade 2)\n\n          -  Patients who are currently receiving treatment with agents that are metabolized\n             predominantly through CYP3A4 and that have a narrow therapeutic window.\n\n          -  Patients with concurrent severe and/or uncontrolled concurrent medical conditions\n             that could compromise participation in the study (i.e. uncontrolled diabetes\n             mellitus, clinically significant pulmonary disease, clinically significant\n             neurological disorder, active or uncontrolled infection).\n\n          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors\n             for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity\n             or hypercoagulability syndromes).\n\n        Other protocol related inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781572", 
            "org_study_id": "CMEK162X2114"
        }, 
        "intervention": [
            {
                "arm_group_label": "Phase Ib", 
                "description": "MEK162 will be administered orally twice daily on a continuous dosing schedule. LEE011 will be administered orally once daily for 21 days followed by a 1 week break (28-day cycle).", 
                "intervention_name": "LEE011 and MEK162", 
                "intervention_type": "Drug", 
                "other_name": "Dosing Schedule 1"
            }, 
            {
                "arm_group_label": "Phase II", 
                "description": "Once the MTD(s)/RP2D have been determined for each tested dose schedule, the phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination.", 
                "intervention_name": "LEE011 and MEK162", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Phase Ib", 
                "description": "MEK162 will be administered orally twice daily and LEE011 will be administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).", 
                "intervention_name": "LEE011 and MEK162", 
                "intervention_type": "Drug", 
                "other_name": "Dosing Schedule 2"
            }, 
            {
                "arm_group_label": "Phase Ib", 
                "description": "MEK162 will be administered orally twice daily and LEE011 will be administered once daily for 2 weeks followed by a 1 week break (21-day cycle).", 
                "intervention_name": "LEE011 and MEK162", 
                "intervention_type": "Drug", 
                "other_name": "Dosing Schedule 3"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 2, 2014", 
        "location": [
            {
                "contact": {
                    "email": "takamuraK@cc.ucsf.edu", 
                    "last_name": "Kathryn Takamura", 
                    "phone": "415-885-7837"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94101"
                    }, 
                    "name": "University of California San Francisco Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Adil Daud", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Amber.Isley@moffitt.org", 
                    "last_name": "Amber Isley", 
                    "phone": "813-745-7631"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute SC - 7"
                }, 
                "investigator": {
                    "last_name": "Geoffrey Gibney", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gail Newth", 
                    "phone": "313-576-9371"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Wayne State University/Karmanos Cancer Institute Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Muaiad Kittaneh", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bialczaa@mskcc.org", 
                    "last_name": "Angelica Bialczak", 
                    "phone": "646-888-4339"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center Dept Oncology"
                }, 
                "investigator": {
                    "last_name": "Michael K. Postow", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bp2304@columbia.edu", 
                    "last_name": "Biljana Popvic", 
                    "phone": "212-305-3846"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center- New York Presbyterian Onc Dept."
                }, 
                "investigator": {
                    "last_name": "Gary K. Schwartz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Barbara.j.broome@vanderbilt.edu", 
                    "last_name": "Barbara J Broome", 
                    "phone": "615-936-5867"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University Medical Center SC - Dept of Oncology ."
                }, 
                "investigator": {
                    "last_name": "Jeffrey A. Sosman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "slister@mdanderson.org", 
                    "last_name": "Shelia Lister", 
                    "phone": "713-563-0536"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas/MD Anderson Cancer Center Dept of Onc."
                }, 
                "investigator": {
                    "last_name": "Kevin B. Kim", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dleatham@uwashington.edu", 
                    "last_name": "Daniel Leatham", 
                    "phone": "206-288-7370"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109-1023"
                    }, 
                    "name": "Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Kim Margolin", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2060"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westmead", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2145"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3084"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45147"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gera", 
                        "country": "Germany", 
                        "zip": "07548"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "30625"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany", 
                        "zip": "80336"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy", 
                        "zip": "80131"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "state": "the Netherlands", 
                        "zip": "3508 GA"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "5800"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands", 
                        "zip": "6525 GA"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "NO-0379"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Germany", 
                "Italy", 
                "Netherlands", 
                "Norway"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To estimate the maximum tolerate doses (MTDs) and/or identify the RP2D and schedule of LEE011 and MEK162 combination.", 
                "measure": "Incidence of dose limiting toxicities (Phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "first 28 days of treatment"
            }, 
            {
                "description": "ORR is the proportion of patients with best overall response of complete response (CR) or partial response (PR) by month 2 assessed according to RECIST 1.1 criteria. ORR is done to describe the anti-tumor activity of LEE011 and MEK162 combination.", 
                "measure": "Objective response rate (ORR) (phase II)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, every 2-4 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781572"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).", 
                "measure": "Plasma concentration-time profile (AUCtau) of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).", 
                "measure": "Plasma concentration-time profile (AUCtau,ss) of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).", 
                "measure": "Plasma concentration-time profile (Cmin,ss) of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "Evaluation of PK parameters, including but not limited to AUCtau, AUCtau,ss, Cmin,ss, Cmax, Cmax,ss ,Tmax, Tmax,ss, accumulation ratio (Racc), and T1/2,acc, CL/F in cycle 1-6. (Phase Ib).", 
                "measure": "Plasma concentration-time profiles of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).", 
                "measure": "Plasma concentration-time profile (Cmax) of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).", 
                "measure": "Plasma concentration-time profile (Cmax,ss) of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).", 
                "measure": "Plasma concentration-time profile (Tmax) of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).", 
                "measure": "Plasma concentration-time profile (Tmax,ss) of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).", 
                "measure": "Plasma concentration-time profile (accumulation ration, Racc) of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).", 
                "measure": "Plasma concentration-time profile (T1/2, acc) of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).", 
                "measure": "Plasma concentration-time profile (CL/F) of LEE011 and MEK162 (phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "description": "Safety and tolerability will be characterized through the incidence and severity of adverse drug reactions, serious adverse drug reactions, changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, dose reduction and dose intensity.", 
                "measure": "Incidence of adverse drug reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Approximatley 12 months after FPFV"
            }, 
            {
                "description": "To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.", 
                "measure": "Duration of Response (DoR) - Phase ll", 
                "safety_issue": "Yes", 
                "time_frame": "Approximatley 12 months after the FPFV"
            }, 
            {
                "description": "To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.", 
                "measure": "Time to Progression (TTP) - Phase ll", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 12 months after the FPFV"
            }, 
            {
                "description": "To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.", 
                "measure": "Progression Free Survival (PFS) - Phase ll", 
                "safety_issue": "Yes", 
                "time_frame": "Approximatley 12 months after the FPFV"
            }, 
            {
                "description": "To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.", 
                "measure": "Overall Survival (OS) - Phase ll", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 12 months after the FPFV"
            }, 
            {
                "description": "To assess clinical safety according to RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.", 
                "measure": "Best Overall Response (BOR) - Phase ll", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 12 months after the FPFV"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}